famotidine has been researched along with Cardiac Failure in 9 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twelve patients with stable congestive heart failure and left ventricular dysfunction were enrolled in a double-blind, randomized crossover trial of famotidine, cimetidine and placebo to determine whether histamine type 2 (H2) antagonists adversely affect left ventricular systolic performance." | 9.07 | Effects of histamine type 2-receptor antagonists cimetidine and famotidine on left ventricular systolic function in chronic congestive heart failure. ( Jarboe, LA; Lee, RT; Solomon, SD; Wolfe, MM; Wolff, S, 1993) |
| "In a randomized, placebo-controlled, double-blind study, 12 patients with congestive heart failure (New York Heart Association class II) were successively treated for 1 week each with placebo, 40 mg famotidine, and 1000 mg quinidine." | 9.07 | Hemodynamic effects of quinidine and famotidine in patients with congestive heart failure. ( Halabi, A; Hinrichsen, H; Kirch, W, 1992) |
| "Histamine has a positive inotropic effect on ventricular myocardium and stimulation of histamine H₂ receptors increases the intracellular cAMP level via Gs protein, as dose stimulation of β-adrenergic receptors, and worsens heart failure." | 7.76 | A histamine H₂ receptor blocker ameliorates development of heart failure in dogs independently of β-adrenergic receptor blockade. ( Asakura, M; Asanuma, H; Fujita, M; Kim, J; Kitakaze, M; Komamura, K; Minamino, T; Sanada, S; Sasaki, H; Sugimachi, M; Takahama, H; Takashima, S; Wakeno, M, 2010) |
| " However, the association of famotidine and acquired long QT syndrome has rarely been reported." | 7.72 | Famotidine and long QT syndrome. ( Hongo, RH; Kayser, SR; Lee, KW; Scheinman, MM; Tseng, ZH, 2004) |
| "Twelve patients with stable congestive heart failure and left ventricular dysfunction were enrolled in a double-blind, randomized crossover trial of famotidine, cimetidine and placebo to determine whether histamine type 2 (H2) antagonists adversely affect left ventricular systolic performance." | 5.07 | Effects of histamine type 2-receptor antagonists cimetidine and famotidine on left ventricular systolic function in chronic congestive heart failure. ( Jarboe, LA; Lee, RT; Solomon, SD; Wolfe, MM; Wolff, S, 1993) |
| "In a randomized, placebo-controlled, double-blind, crossover comparison, 12 patients with congestive heart failure (New York Heart Association class II) and dyspeptic complaints were treated orally for 1 week each with placebo, 40 mg omeprazole daily, and 40 mg famotidine daily." | 5.07 | Cardiovascular effects of omeprazole and famotidine. ( Halabi, A; Kirch, W, 1992) |
| "In a randomized, placebo-controlled, double-blind study, 12 patients with congestive heart failure (New York Heart Association class II) were successively treated for 1 week each with placebo, 40 mg famotidine, and 1000 mg quinidine." | 5.07 | Hemodynamic effects of quinidine and famotidine in patients with congestive heart failure. ( Halabi, A; Hinrichsen, H; Kirch, W, 1992) |
| "Histamine has a positive inotropic effect on ventricular myocardium and stimulation of histamine H₂ receptors increases the intracellular cAMP level via Gs protein, as dose stimulation of β-adrenergic receptors, and worsens heart failure." | 3.76 | A histamine H₂ receptor blocker ameliorates development of heart failure in dogs independently of β-adrenergic receptor blockade. ( Asakura, M; Asanuma, H; Fujita, M; Kim, J; Kitakaze, M; Komamura, K; Minamino, T; Sanada, S; Sasaki, H; Sugimachi, M; Takahama, H; Takashima, S; Wakeno, M, 2010) |
| " However, the association of famotidine and acquired long QT syndrome has rarely been reported." | 3.72 | Famotidine and long QT syndrome. ( Hongo, RH; Kayser, SR; Lee, KW; Scheinman, MM; Tseng, ZH, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, YH | 1 |
| Cai, WK | 1 |
| Yin, SJ | 1 |
| Wang, P | 1 |
| Li, ZR | 1 |
| Yang, Q | 1 |
| Zhou, T | 1 |
| Meng, R | 1 |
| Yang, M | 1 |
| Guo, Y | 1 |
| He, GH | 1 |
| Takahama, H | 1 |
| Asanuma, H | 2 |
| Sanada, S | 2 |
| Fujita, M | 2 |
| Sasaki, H | 1 |
| Wakeno, M | 2 |
| Kim, J | 2 |
| Asakura, M | 2 |
| Takashima, S | 2 |
| Minamino, T | 2 |
| Komamura, K | 2 |
| Sugimachi, M | 1 |
| Kitakaze, M | 2 |
| Lee, KW | 1 |
| Kayser, SR | 1 |
| Hongo, RH | 1 |
| Tseng, ZH | 1 |
| Scheinman, MM | 1 |
| Ogai, A | 1 |
| Hirata, A | 1 |
| Tsukamoto, O | 1 |
| Shinozaki, Y | 1 |
| Myoishi, M | 1 |
| Tomoike, H | 1 |
| Kolck, UW | 1 |
| Alfter, K | 1 |
| Homann, J | 1 |
| von Kügelgen, I | 1 |
| Molderings, GJ | 1 |
| Solomon, SD | 1 |
| Wolff, S | 1 |
| Jarboe, LA | 1 |
| Wolfe, MM | 1 |
| Lee, RT | 1 |
| Halabi, A | 2 |
| Kirch, W | 2 |
| Hinrichsen, H | 1 |
| Berlin, RG | 1 |
3 trials available for famotidine and Cardiac Failure
| Article | Year |
|---|---|
Effects of histamine type 2-receptor antagonists cimetidine and famotidine on left ventricular systolic function in chronic congestive heart failure.
Topics: Aged; Analysis of Variance; Chronic Disease; Cimetidine; Double-Blind Method; Echocardiography; Famo | 1993 |
Cardiovascular effects of omeprazole and famotidine.
Topics: Aged; Cardiac Output; Double-Blind Method; Dyspepsia; Famotidine; Female; Heart Failure; Hemodynamic | 1992 |
Hemodynamic effects of quinidine and famotidine in patients with congestive heart failure.
Topics: Cardiac Output; Double-Blind Method; Famotidine; Female; Heart Failure; Hemodynamics; Humans; Male; | 1992 |
6 other studies available for famotidine and Cardiac Failure
| Article | Year |
|---|---|
Histamine H2 receptor antagonist exposure was related to decreased all-cause mortality in critical ill patients with heart failure: a cohort study.
Topics: Cohort Studies; Critical Illness; Famotidine; Heart Failure; Histamine H2 Antagonists; Humans; Ranit | 2022 |
A histamine H₂ receptor blocker ameliorates development of heart failure in dogs independently of β-adrenergic receptor blockade.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Cardiac Catheterization; Cardiac Pacing, Artificia | 2010 |
Famotidine and long QT syndrome.
Topics: Aged; Aged, 80 and over; Diagnosis, Differential; Electrocardiography; Famotidine; Heart Failure; Hi | 2004 |
Blockade of histamine H2 receptors protects the heart against ischemia and reperfusion injury in dogs.
Topics: Animals; Dogs; Famotidine; Heart Failure; Hemodynamics; Histamine H2 Antagonists; Myocardial Ischemi | 2006 |
Cardiac mast cells: implications for heart failure.
Topics: Chronic Disease; Famotidine; Female; Heart Failure; Humans; Male; Mast Cells; Mastocytosis, Systemic | 2007 |
Famotidine does not have a negative inotropic effect.
Topics: Animals; Depression, Chemical; Dogs; Famotidine; Heart Failure; Humans; Myocardial Contraction; Rats | 1987 |